JP3598366B2 - Biologically active cyclic nucleotide derivative and method for producing the same - Google Patents
Biologically active cyclic nucleotide derivative and method for producing the same Download PDFInfo
- Publication number
- JP3598366B2 JP3598366B2 JP2000250956A JP2000250956A JP3598366B2 JP 3598366 B2 JP3598366 B2 JP 3598366B2 JP 2000250956 A JP2000250956 A JP 2000250956A JP 2000250956 A JP2000250956 A JP 2000250956A JP 3598366 B2 JP3598366 B2 JP 3598366B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclic nucleotide
- nucleotide derivative
- same
- producing
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004122 cyclic group Chemical group 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 10
- 229940095074 cyclic amp Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- -1 2-aminoethylcarbamoyl Chemical group 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- SPIBZEPRKOHURV-UHFFFAOYSA-N carbonic acid;n,n-dibutylbutan-1-amine Chemical compound OC(O)=O.CCCCN(CCCC)CCCC SPIBZEPRKOHURV-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 0 **NC(OC(C[n]1c2nc(*)nc(*)c2nc1)(COC1)C1(CCO1)OP1(O)=O)=O Chemical compound **NC(OC(C[n]1c2nc(*)nc(*)c2nc1)(COC1)C1(CCO1)OP1(O)=O)=O 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- 241000224495 Dictyostelium Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108091008885 GPCRs class E Proteins 0.000 description 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Saccharide Compounds (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、細胞内情報伝達機構の研究に有用な、新規な環状ヌクレオチド誘導体及びその製造方法に関する。
【０００２】
【従来の技術】
環状ＡＭＰ（ｃＡＭＰ）および環状ＧＭＰ（ｃＧＭＰ）は細胞内情報伝達に重要な役割を持つ環状ヌクレオチドである。この環状ヌクレオチドが細胞内でどのように機能するのか、あるいは受容体タンパク質とどのように相互作用するのかを研究することは細胞生物学的な知的価値とともに疾病の機構やこれに対する医薬品開発のために必須である。こうした研究において、環状ヌクレオチドに蛍光プローブを結合させた蛍光性環状ヌクレオチド誘導体は細胞内の環状ヌクレオチドの機能動態を解析する研究の効率と質を向上させるのに有用である。
【０００３】
これまでの環状ヌクレオチド誘導体は主に医薬品を目的として開発されており、ホスホジエステラーゼ（ＰＤＥ）の阻害効果を持つものとして合成されている。しかし、環状ヌクレオチドの細胞内機能動態・細胞膜上の受容体との相互作用を調べるためには、修飾によってその生理活性が損なわれてはならない。このために、アデニン環やリン酸部位への修飾を回避し、生理活性にもっとも影響の少ないリボースの修飾を選択的に行う必要がある。また、蛍光性環状ヌクレオチド誘導体を合成する場合、生物学系の一般研究者が通常の方法では環状ヌクレオチドに蛍光プローブを導入することは容易ではない。
【０００４】
【発明が解決しようとする課題】
したがって、本発明は、環状ヌクレオチドの細胞内機能動態や細胞膜上の受容体との相互作用を調べるのに有用な、蛍光団を有する公知の色素と容易に縮合することのできる、反応前駆体となる新規な環状ヌクレオチド誘導体及びその製造方法を提供することを目的とする。
【０００５】
【課題を解決するための手段】
本発明者らは鋭意検討した結果、ｃＡＭＰ誘導体のリボースの水酸基に、反応性の高い−ＮＨ２基或いは−ＳＨ基を適当な長さのリンカーを加えて導入することにより、目的とする環状ヌクレオチド誘導体が得られることを見出し、本発明を完成したものである。
すなわち、本発明はつぎのような構成を有する。
【０００６】
１．次の一般式（１）で表される環状ヌクレオチド誘導体。
【０００７】
【化６】
（式中、Ｒ１は−ＯＨ又は−ＮＨ２を表し、Ｒ２は水素又は−ＮＨ２を表し、Ｒ３は −ＮＨ２又は−ＳＨを表す。また、ｎは２〜４の整数を表す。）
２．次の一般式（２）で表される環状ヌクレオチドを
【０００９】
【化７】
（式中、Ｒ１は−ＯＨ又は−ＮＨ２を表し、Ｒ２は水素又は−ＮＨ２を表す。）
式（３）で表される１，１’−カルボニルジイミダゾールと反応させて、
【００１１】
【化８】
得られる一般式（４）で表される環状ヌクレオチド中間体を、
【００１３】
【化９】
（式中、Ｒ１及びＲ２は上記と同じである。）
一般式（５）で表される化合物と反応させることを特徴とする、
Ｈ２Ｎ（ＣＨ２）ｎＲ３ （５）
（式中、Ｒ３は −ＮＨ２又は−ＳＨを表し、ｎは２〜４の整数を表す。）
一般式（１）で表される環状ヌクレオチド誘導体の製造方法。
【００１５】
【化１０】
（式中、Ｒ１，Ｒ２及びＲ３は上記と同じである。）
【００１７】
【発明の実施の形態】
本発明の１例としてｃＡＭＰから目的とする２’−Ｏ−（２−アミノエチルカルバモイル）ｃＡＭＰを得る反応スキームを以下に示す。
【００１８】
【化１１】
本発明で得られる一般式（１）で表される新規な環状ヌクレオチド誘導体は、例えばＣｙ３−ＯＳｕ（商品名：アマーシャム ファルマシア バイオテク社製）のような、環状ヌクレオチド（１）のＲ３と反応性を有する公知の蛍光色素と縮合させて、Ｃｙ３−ＥＤＡ−ｃＡＭＰのような蛍光性環状ヌクレオチド誘導体を製造するのに使用される。この蛍光性環状ヌクレオチド誘導体は、細胞内における環状ヌクレオチドの機能動態を解析する研究の効率と質を向上させるのに有用である。
【００２０】
【実施例】
［２’−Ｏ−（２−アミノエチルカルバモイル）ｃＡＭＰの合成］
市販のｃＡＭＰ６．０ｇ（１８．２ｍｍｏｌ）をＭｏｌｅｃｕｌａｒ Ｓｉｅｖｅｓ ４Ａ（製品名：Ｋ，Ｎａアルミノシリケート）で乾燥したジメチルホルムアミド（ＤＭＦ）６００ｍｌに溶解し、トリブチルアミン４．３６ｍｌを添加後、１，１’−カルボニルジイミダゾール１６．８ｇ（１０４ｍｍｏｌ）を加えて室温で１時間攪拌した。さらに、ＤＭＦ６００ｍｌを加え、室温で３０分間攪拌後、加温し３０℃で１．５時間攪拌した。つぎに、エチレンジアミン１２ｍｌを添加し、３０℃で３時間攪拌後、濾過して不溶物を除去した。不溶物を高速液体クロマトグラフィー（ＨＰＬＣ）により分析したところ、殆どが未反応のｃ−ＡＭＰであった。
濾過した溶液を６０℃の水浴上で減圧濃縮し、微黄色の油状物３５．４ｇを得た。ジクロロエタン６００ｍｌを加えて室温で３０分攪拌し、結晶を濾取し、ジエチルエーテルで洗浄後、減圧乾燥して白色の粉末１３ｇを得た。
この粉末を３バッチに分けて水に溶解させ、カラムとしてＤａｉｓｏｇｅｌ ＳＰ−１２０−３０／５０−ＯＤＳ−Ｂ（５０ｍｍＩ．Ｄ．ｘ５００ｍｍ）を使用し、２５４ｎｍのＵＶで検出しながら、１０ｍＭ Ｔｒｉｂｕｔｙｌａｍｍｏｎｉｕｍ Ｂｉｃａｒｂｏｎａｔｅ（トリブチルアミン−重炭酸バッファー）−１０％メタノールで１５ｍｌ／ｍｉｎで溶出させた。目的とする画分を分取後、メタノールを減圧留去し、凍結乾燥した。得られた固体にメタノールを加えて減圧濃縮操作を３回繰り返し、白色固体２．２７ｇを得た。この固体のＨＰＬＣで測定した純度は９９．４％であり、１Ｈ−ＮＭＲによって目的産物であることを確認した。
１Ｈ−ＮＭＲ（Ｄ２Ｏ）：δ８．０６（ｓ，１Ｈ），８．０３（ｓ，１Ｈ），６．１５（ｓ，１Ｈ），５．３８（ｄ，１Ｈ，Ｊ＝７Ｈｚ），４．８２（ｍ，１Ｈ），４．３４（ｍ，１Ｈ），４．１〜４．２（ｍ，２Ｈ），３．２〜３．４（ｍ，２Ｈ），２．９５（ｔ，２Ｈ，Ｊ＝５．５Ｈｚ）
【００２１】
この環状ヌクレオチド誘導体が有効なアナログとして機能することは、粘菌の環状ＡＭＰに対する走化性応答によって明らかにした。細胞性粘膜（Ｄｉｃｔｙｏｓｔｅｌｉｕｍ ｄｉｓｃｏｉｄｉｕｍ）はｃＡＭＰを走化性物質（アトラクタント）とする。飢餓状態にして培養した粘菌細胞は細胞集塊となり子実体形成を開始する。この細胞塊はｃＡＭＰに対する感受性が高く細胞膜上にｃＡＭＰ受容体を数多く発現している。無栄養寒天培地に上記実施例で得られたヌクレオチド誘導体を１０−８から１０−５Ｍの濃度で加え、円形の培養器で固めた。この培地の中央に細胞塊（２μＬ）を載せて２０℃で３時間培養した。３時間後に細胞塊の広がりを測定して細胞の移動速度を求めた結果を図１に示す。この環状ヌクレオチド誘導体では、無修飾のｃＡＭＰに対する反応と同様の濃度と強度で細胞の移動速度の反応が得られた。
【００２２】
また、この環状ヌクレオチド誘導体に蛍光色素ｃｙ３−ＯＳｕを縮合させて蛍光性環状ヌクレオチド誘導体ｃｙ３−ＥＤＡ−ｃＡＭＰを合成し、同様にして細胞の移動速度を求めたところ、ｃＡＭＰと同様の反応を得た。（図１参照）
したがって、この蛍光性環状ヌクレオチド誘導体を使用すれば、細胞内の環状ヌクレオチドの機能動態を解析する研究の効率と質を向上させることができる。
【図面の簡単な説明】
【図１】本発明の環状ヌクレオチド誘導体及び該誘導体から得られる蛍光性環状ヌクレオチド誘導体を使用して、細胞の移動速度を求めた結果を示す図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a novel cyclic nucleotide derivative useful for studying the intracellular signal transduction mechanism and a method for producing the same.
[0002]
[Prior art]
Cyclic AMP (cAMP) and cyclic GMP (cGMP) are cyclic nucleotides with important roles in intracellular signaling. Studying how this cyclic nucleotide functions in cells or how it interacts with receptor proteins is not only for the intellectual value of cell biology, but also for the mechanism of disease and the development of drugs against it. Required for In such studies, a fluorescent cyclic nucleotide derivative in which a fluorescent probe is bound to a cyclic nucleotide is useful for improving the efficiency and quality of studies for analyzing the functional dynamics of cyclic nucleotides in cells.
[0003]
Conventional cyclic nucleotide derivatives have been developed mainly for pharmaceuticals, and have been synthesized as having a phosphodiesterase (PDE) inhibitory effect. However, in order to examine the dynamics of intracellular functions of cyclic nucleotides and their interaction with receptors on cell membranes, the modifications must not impair their biological activities. For this purpose, it is necessary to avoid modification to the adenine ring or the phosphate site and selectively carry out ribose modification which has the least effect on the physiological activity. In addition, when synthesizing a fluorescent cyclic nucleotide derivative, it is not easy for a general biological researcher to introduce a fluorescent probe into a cyclic nucleotide by an ordinary method.
[0004]
[Problems to be solved by the invention]
Therefore, the present invention is useful for investigating the intracellular functional dynamics of cyclic nucleotides and the interaction with receptors on the cell membrane, and a reaction precursor that can be easily condensed with a known dye having a fluorophore. It is an object of the present invention to provide a novel cyclic nucleotide derivative and a method for producing the same.
[0005]
[Means for Solving the Problems]
The present inventors have conducted intensive studies, and as a result, by introducing a highly reactive -NH 2 group or -SH group to a hydroxyl group of ribose of a cAMP derivative by adding a linker having an appropriate length, a desired cyclic nucleotide is obtained. The inventors have found that a derivative can be obtained, and have completed the present invention.
That is, the present invention has the following configuration.
[0006]
1. A cyclic nucleotide derivative represented by the following general formula (1).
[0007]
Embedded image
(Wherein, R 1 represents —OH or —NH 2 , R 2 represents hydrogen or —NH 2 , R 3 represents —NH 2 or —SH, and n represents an integer of 2 to 4. .)
2. The cyclic nucleotide represented by the following general formula (2) is
Embedded image
(Wherein, R 1 represents —OH or —NH 2 , and R 2 represents hydrogen or —NH 2. )
By reacting with 1,1′-carbonyldiimidazole represented by the formula (3),
[0011]
Embedded image
The obtained cyclic nucleotide intermediate represented by the general formula (4) is
[0013]
Embedded image
(In the formula, R 1 and R 2 are the same as described above.)
Characterized by reacting with a compound represented by the general formula (5),
H 2 N (CH 2 ) n R 3 (5)
(In the formula, R 3 represents —NH 2 or —SH, and n represents an integer of 2 to 4.)
A method for producing a cyclic nucleotide derivative represented by the general formula (1).
[0015]
Embedded image
(In the formula, R 1 , R 2 and R 3 are the same as described above.)
[0017]
BEST MODE FOR CARRYING OUT THE INVENTION
As an example of the present invention, a reaction scheme for obtaining desired 2′-O- (2-aminoethylcarbamoyl) cAMP from cAMP is shown below.
[0018]
Embedded image
The novel cyclic nucleotide derivative represented by the general formula (1) obtained in the present invention has a reactivity with R 3 of the cyclic nucleotide (1) such as Cy3-OSu (trade name: manufactured by Amersham Pharmacia Biotech). And used to produce a fluorescent cyclic nucleotide derivative such as Cy3-EDA-cAMP. This fluorescent cyclic nucleotide derivative is useful for improving the efficiency and quality of research for analyzing the functional dynamics of cyclic nucleotides in cells.
[0020]
【Example】
[Synthesis of 2'-O- (2-aminoethylcarbamoyl) cAMP]
6.0 g (18.2 mmol) of commercially available cAMP was dissolved in 600 ml of dimethylformamide (DMF) dried with Molecular Sieves 4A (product name: K, Na aluminosilicate), and 4.36 ml of tributylamine was added. 16.8 g (104 mmol) of -carbonyldiimidazole was added, and the mixture was stirred at room temperature for 1 hour. Further, 600 ml of DMF was added, and the mixture was stirred at room temperature for 30 minutes, and then heated and stirred at 30 ° C. for 1.5 hours. Next, 12 ml of ethylenediamine was added, and the mixture was stirred at 30 ° C. for 3 hours, and then filtered to remove insolubles. When the insolubles were analyzed by high performance liquid chromatography (HPLC), most were unreacted c-AMP.
The filtered solution was concentrated under reduced pressure on a water bath at 60 ° C. to obtain 35.4 g of a pale yellow oil. After adding 600 ml of dichloroethane and stirring at room temperature for 30 minutes, the crystals were collected by filtration, washed with diethyl ether, and dried under reduced pressure to obtain 13 g of a white powder.
This powder was divided into three batches, dissolved in water, and used as a column using Daisogel SP-120-30 / 50-ODS-B (50 mm ID × 500 mm), while detecting with UV at 254 nm, and using 10 mM Tributylammonium Bicarbonate (UV). It was eluted with tributylamine-bicarbonate buffer) -10% methanol at 15 ml / min. After fractionation of the desired fraction, methanol was distilled off under reduced pressure and freeze-dried. Methanol was added to the obtained solid, and the procedure of concentration under reduced pressure was repeated three times to obtain 2.27 g of a white solid. The purity of this solid measured by HPLC was 99.4%, and it was confirmed by 1 H-NMR that it was the desired product.
1 H-NMR (D2O): δ 8.06 (s, 1H), 8.03 (s, 1H), 6.15 (s, 1H), 5.38 (d, 1H, J = 7 Hz), 4. 82 (m, 1H), 4.34 (m, 1H), 4.1 to 4.2 (m, 2H), 3.2 to 3.4 (m, 2H), 2.95 (t, 2H, J = 5.5 Hz)
[0021]
The ability of this cyclic nucleotide derivative to function as an effective analog was demonstrated by the chemotactic response of slime mold to cyclic AMP. Cellular mucosa (Dictyostelium discoidium) uses cAMP as a chemotactic substance (attractant). The slime mold cells cultured under starvation become cell clumps and start to form fruiting bodies. This cell mass is highly sensitive to cAMP and expresses many cAMP receptors on the cell membrane. The nucleotide derivative obtained in the above example was added to the nutrient agar medium at a concentration of 10 −8 to 10 −5 M, and the mixture was solidified in a circular incubator. A cell mass (2 μL) was placed on the center of this medium and cultured at 20 ° C. for 3 hours. FIG. 1 shows the results obtained by measuring the spread of the cell mass after 3 hours to determine the moving speed of the cells. With this cyclic nucleotide derivative, a response at a cell migration rate was obtained at the same concentration and intensity as the response to unmodified cAMP.
[0022]
In addition, a fluorescent dye cy3-OSu was condensed with this cyclic nucleotide derivative to synthesize a fluorescent cyclic nucleotide derivative cy3-EDA-cAMP. When the cell migration rate was determined in the same manner, a reaction similar to that of cAMP was obtained. . (See Fig. 1)
Therefore, the use of this fluorescent cyclic nucleotide derivative can improve the efficiency and quality of research for analyzing the functional dynamics of cyclic nucleotides in cells.
[Brief description of the drawings]
FIG. 1 is a diagram showing the results of determining the cell migration rate using a cyclic nucleotide derivative of the present invention and a fluorescent cyclic nucleotide derivative obtained from the derivative.
Claims (2)
式（３）で表される１，１’−カルボニルジイミダゾールと反応させて、
一般式（５）で表される化合物と反応させることを特徴とする、
Ｈ２Ｎ（ＣＨ２）ｎＲ３ （５）
（式中、Ｒ３は −ＮＨ２又は−ＳＨを表し、ｎは２〜４の整数を表す。）
一般式（１）で表される環状ヌクレオチド誘導体の製造方法。
By reacting with 1,1′-carbonyldiimidazole represented by the formula (3),
Characterized by reacting with a compound represented by the general formula (5),
H 2 N (CH 2 ) n R 3 (5)
(In the formula, R 3 represents —NH 2 or —SH, and n represents an integer of 2 to 4.)
A method for producing a cyclic nucleotide derivative represented by the general formula (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000250956A JP3598366B2 (en) | 2000-08-22 | 2000-08-22 | Biologically active cyclic nucleotide derivative and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000250956A JP3598366B2 (en) | 2000-08-22 | 2000-08-22 | Biologically active cyclic nucleotide derivative and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002069092A JP2002069092A (en) | 2002-03-08 |
| JP3598366B2 true JP3598366B2 (en) | 2004-12-08 |
Family
ID=18740445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000250956A Expired - Lifetime JP3598366B2 (en) | 2000-08-22 | 2000-08-22 | Biologically active cyclic nucleotide derivative and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3598366B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4902958B2 (en) * | 2002-06-07 | 2012-03-21 | ユニバーシテール・メディッシュ・セントラム・ユトレヒト | Novel compounds for modulating the activity of exchange protein (Epac) directly activated by cAMP |
-
2000
- 2000-08-22 JP JP2000250956A patent/JP3598366B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002069092A (en) | 2002-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trost et al. | A versatile enantioselective strategy toward L-C-nucleosides: A total synthesis of L-Showdomycin | |
| JPH06503838A (en) | Backbone-modified oligonucleotide analogs | |
| JP5419278B2 (en) | Fluorogenic molecule | |
| DE60123056T2 (en) | BASE ANALOG | |
| JP2005509028A (en) | Process for the synthesis of aspartic and glutamic acid derivatives and their diazoketone intermediates | |
| CN112876392B (en) | Near-infrared fluorescent probe for detecting cysteine based on isothiocyanate structure specificity and preparation method and application thereof | |
| CN109438448B (en) | Indolo-heptatomic ring compound and preparation method and application thereof | |
| FR2470774A1 (en) | NUCLEOSIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USES | |
| CN113956266B (en) | A method for large-scale synthesis of tetrodotoxin | |
| CN116375692B (en) | Near infrared fluorescent molecular probe for detecting cysteine, preparation method and kit thereof | |
| JP3598366B2 (en) | Biologically active cyclic nucleotide derivative and method for producing the same | |
| US5210203A (en) | Sulfonamide-derivative compounds for tagging nucleic acid probes | |
| CN112079823B (en) | Near-infrared frequency up-conversion fluorescence molecular probe, preparation method and application | |
| EP0209996A2 (en) | Nucleic acid probes comprising N4 -(substituted amino)cytidines | |
| WO2022138748A1 (en) | Labeling method, oxidant for labeling, ruthenium complex, catalyst, labeling compound, and compound | |
| e Silva et al. | Synthesis and cytotoxic activity of N-substituted thiosemicarbazones of 3-(3, 4-methylenedioxy) phenylpropanal | |
| CN112778189A (en) | (3R,4S) -N-substituent-3-carboxylic acid-4-ethyl pyrrolidine, intermediate and lapatinib | |
| JP2019196349A (en) | Compound, fluorescence label induction agent, and fluorescence label induction method | |
| CN114213490B (en) | Tricyclic nucleotide analogues and synthetic method and application thereof | |
| JP2560250B2 (en) | Process for producing natural sphingosines and their synthetic intermediates | |
| AU2006325622B2 (en) | A manufacturing process of 2',2'-difluoronucleoside and intermediate | |
| JP3025559B2 (en) | Adenosine derivatives | |
| JPH05271224A (en) | New nucleoside derivative containing oxetane ring | |
| CN117700369A (en) | Preparation method of 2- (2-chloropyrimidine-5-yl) acetic acid/ester | |
| WO2025129984A1 (en) | Synthesis method for pyrimidine locked nucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040803 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3598366 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |